Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 2, 2010, Pages 148-152

  William, William N ^a   Khuri, Fadlo R ^b   Fossella, Frank V ^a   Glisson, Bonnie S ^a   Zinner, Ralph G ^a   Lee, J Jack ^a   Herbst, Roy S ^a   Lippman, Scott M ^a   Kim, Edward S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Docetaxel; Frontline; Non small cell lung cancer; Second line; Vinorelbine

Indexed keywords

DEXAMETHASONE; DOCETAXEL; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COUGHING; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; EDEMA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HEARING LOSS; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMATURIA; HEMOPTYSIS; HEMORRHOID; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOTENSION; INFECTION; INSOMNIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRURITUS; SKIN EXFOLIATION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 77951036525     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318199fb99     Document Type: Article

References (28)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
2. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016-3024.
3. Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced non-small-cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer. 1998;82:116-126.
4. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small-cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small-cell lung cancer. Br J Cancer. 2000;83: 447-453.
5. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999;91:66-72.
6. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362-372.
7. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24:3657-3663. (Pubitemid 46630541)
8. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:1074-1080.
9. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or nonresectable localized non-small-cell lung cancer (NSCLC). Lung Cancer. 2000;27:145-157.
10. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
11. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-1597.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
13. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus nonplatinum- based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23:2926-2936.
14. Kourousis C, Androulakis N, Kakolyris S, et al. First-line treatment of advanced non-small-cell lung carcinoma with docetaxel and vinorelbine. Cancer. 1998;83:2083-2090.
15. Bennouna J, Monnier A, Riviere A, et al. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-smallcell lung cancer. Eur J Cancer. 2000;36:1107-1112.
16. Munoz A, Rubio I, Mane JM, et al. Phase II study of docetaxel/vinorelbine in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy. Clin Lung Cancer. 2002;4:168-173.
17. Hainsworth JD, Burris HA III, Billings FT III, et al. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced non-small-cell lung carcinoma: phase II trials of the Minnie Pearl Cancer Research Network. Cancer. 2001;92:2391-2398.
18. Nelli F, Naso G, De Pasquale Ceratti A, et al. Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small-cell lung cancer patients: a phase I-II trial. J Chemother. 2004;16:392-399.
19. Leu KM, Kim KM, Larson M, et al. Phase I/II trial of docetaxel and vinorelbine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer. 2001;34:105-113.
20. Miller VA, Krug LM, Ng KK, et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000; 18:1346-1350.
21. Page RD, Smith FP, Geils GF, et al. Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced non-small-cell lung carcinoma. Cancer. 2005;104:1956-1961.
22. Sanchez JM, Balana C, Font A, et al. Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. Lung Cancer. 2002;38:309-315.
23. Soon Y, Stockler MR, Boyer M, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: an updated systematic review and meta-analysis. J Clin Oncol. 2008;26. Abstract 8013.
24. Lara PN Jr, Redman MW, Kelly K, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008;26:463-467.
25. Budman DR, Calabro A, Kreis W. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs. 2002;13:1011-1016.
26. Budman DR, Calabro A. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat. 2002;74:41-46.
27. Aoe K, Kiura K, Ueoka H, et al. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res. 1999;19:291-299. (Pubitemid 29168252)
28. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:2741-2746.